PEPTIDE THERAPY
CATALOG

CRE8
PHARMACY

CRE8 PHARMACY 3700 NW 126th Avenue, Coral Springs, FL 33065 888-224-5181 Toll Free 754-529-8294 Fax

BPC-157

PEPTIDE THERAPY

BENEFITS MAY INCLUDE

- Supports cognitive performance
- Supports joint health
- Protects against drug-induced damage
- Restores the serotogenic transport system
- Protects dopaminergic system
- Enhances the GABAergic system
- Reverse opioid tolerance
- Accelerated wound healing
- Ligament healing (knee, rotary)
- Benefits for ulcers in the stomach
- Benefits for intestinal damage
- May help irritable bowel disease
- Promotes lipolysis
- Improves overall skin appearance
- Repairs skin barrier proteins



BRIEF OVERVIEW

BPC 157, composed of 15 amino acids, is a partial sequence of body protection compound (BPC) that is discovered in and isolated from human gastric juice. Experimentally it has been demonstrated to accelerate the healing of many different wounds, including tendons, muscles, nervous system and superior healing of damaged ligaments. Those who suffer from discomfort due to muscle sprains, tears and damage may benefit from treatment with this peptide. It can also help aid skin burns to heal at a faster rate and increase blood flow to damaged tissues.

COMMON FORMULAS & PROTOCOLS

BPC-157 (10mg) Lyophilized Vial - 300mcg SQ injection nightly for 30 days
BPC-157 (500mcg) Capsule - One capsule daily for 30 days
BPC-157 (500mcg) Sublingual Troche - One troche daily for 30 days
BPC-157 (500mcg) Suppository - One suppository daily for 30 days
BPC-157 (1mg/g) Anti-Inflammatory Cream - Apply 1/4g - 1g daily for 30 days
BPC-157 (1mg/g) Organic Bio-Cream (facial) - Apply 1-2 pumps daily for 30 days

CLINICAL REFERENCES

1. Cerovecki, Tomislav; Bojanic, Ivan; Brcic, Luka; Radic, Bozo; Vukoja, Ivan; Seiwerth, Sven; Sikiric, Predrag (September 2010). "Pentadecapeptide BPC 157 (PL 14736) improves ligament healing in the rat". Journal of Orthopaedic Research. 28 (9): 1155–1161. doi:10.1002/jor.21107. ISSN 1554-527X. PMID 20225319.
2. "Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease (PL-10, PLD-116, PL 14736, Pliva, Croatia). Full and distended stomach, and vascular response". PMID 17186181.

Additional references available. Contact us for more info.

CRE8 PHARMACY

CRE8 PHARMACY 3700 NW 126th Avenue, Coral Springs, FL 33065 888-224-5181 Toll Free 754-529-8294 Fax

BREMELANOTIDE (PT-141)

PEPTIDE THERAPY

BENEFITS MAY INCLUDE

- HSDD (hypoactive sexual desire disorder) in premenopausal women.
- Beneficial for low libido (male & female)
- Increase energy
- Beneficial for ED (erectile dysfunction)
- Helps enhance sexual satisfaction
- Skin pigmentation (sunless tanning agent)



BRIEF OVERVIEW

PT-141 (Bremelanotide) is a synthetic peptide developed from Melanotan 2 (MT-II). PT-141 is used for the treatment of erectile dysfunction or impotence in men and HSDD (hypoactive sexual desire disorder) in women. PT-141 is a peptide that was originally developed as a sunless tanning agent. It is a melanocyte-stimulating hormone (MSH) that affects sexual arousal, aiding enhanced libido levels and penile erections. Unlike all PDES inhibitors, PT-141 does not target the vascular system. Instead, it acts on the nervous system via activation of neurons in the hypothalamus to increase sexual desire.

COMMON FORMULAS & PROTOCOLS

Bremelanotide (PT-141) 10,000mcg/ml w/ B6 50mg/ml - 2ml Vial

- 0.1ml SQ injection 30 minutes to 6 hours prior to sexual activity for males
- 0.2ml SQ injection 30 minutes to 6 hours prior to sexual activity for females

Bremelanotide (PT-141) w/B6 (5/25mg/ml) Nasal Spray 10ml Bottle

- 2-4 sprays per nostril 30-60 minutes prior to sexual activity

CLINICAL REFERENCES

1. Shadiack AM, Sharma SD, Earle DC, Spana C, Hallam TJ. 2007;7(11):1137-44. Melanocortins in the treatment of male and female sexual dysfunction.
2. Rosen RC[1], Diamond LE, Earle DC, Shadiack AM, Molinoff PB _2004 Apr;16(2):135-42. Evaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141, a melanocortin receptor agonist, in healthy male subjects and in patients with an inadequate response to Viagra.

Additional references available. Contact us for more info.

CRE8 PHARMACY

CRE8 PHARMACY 3700 NW 126th Avenue, Coral Springs, FL 33065 888-224-5181 Toll Free 754-529-8294 Fax

CJC-1295

PEPTIDE THERAPY

BENEFITS MAY INCLUDE

- Increased protein synthesis
- Promotes lipolysis
- Improves sleep quality
- Increased bone density
- Accelerated injury recovery
- Improved immune system
- Increased protein synthesis
- Increased energy
- Increased IGF-1
- Increase in lean body mass



BRIEF OVERVIEW

CJC-1295 is 30 amino acid peptide hormone that has shown promising and amazing results as a Growth Hormone Releasing Hormone (GHRH) analog. Research supports that CJC-1295 stimulates HGH secretion and can provide a steady increase of HGH with minimal effect on cortisol and prolactin levels. This means increased protein synthesis thus promoting growth and fat loss simultaneously.

COMMON FORMULAS & PROTOCOLS

CJC-1295 (10mg) Lyophilized Vial - 300mcg SQ injection nightly for 30 days
CJC-1295 / Ipamorelin (4/4mg) Lyophilized Vial - 200/200mcg daily SQ injection 5 days on, 2 days off
CJC-1295 / Ipamorelin (5/9mg) Lyophilized Vial - 250/450mcg daily SQ injection 5 days on, 2 days off
CJC-1295 (500mcg) Sublingual Troche - One troche daily for 30 days
CJC-1295 / Ipamorelin (300/300mcg) Sublingual Troche - One troche daily for 30 days

CLINICAL REFERENCES

1. Teichman, Sam L.; Neale, Ann; Lawrence, Betty; Gagnon, Catherine; Castaigne, Jean-Paul; Frohman, Lawrence A. (2006). "Prolonged Stimulation of Growth Hormone (GH) and Insulin-Like Growth Factor I Secretion by CJC-1295, a Long-Acting Analog of GH-Releasing Hormone, in Healthy Adults". *The Journal of Clinical Endocrinology & Metabolism*. 91 (3): 799–805. doi:10.1210/jc.2005-1536. ISSN 0021-972X. PMID 16352683.
2. Ionescu, Madalina; Frohman, Lawrence A. (2006). "Pulsatile Secretion of Growth Hormone (GH) Persists during Continuous Stimulation by CJC-1295, a Long-Acting GH-Releasing Hormone Analog". *The Journal of Clinical Endocrinology & Metabolism*. 91 (12): 4792–4797. doi:10.1210/jc.2006-1702. ISSN 0021-972X.

Additional references available. Contact us for more info.

CRE8 PHARMACY

CRE8 PHARMACY 3700 NW 126th Avenue, Coral Springs, FL 33065 888-224-5181 Toll Free 754-529-8294 Fax

DIHEXA

PEPTIDE THERAPY

BENEFITS MAY INCLUDE

- Improves cognitive function
- Helps in the treatment of Alzheimer's Disease and Parkinson's Disease
- Improves long and short-term memory
- Helps manage depression
- Enhances creative thinking and social interaction
- Improved heart health
- Improves brain focus

BRIEF OVERVIEW

Dihexa, also known as N-hexanoic-Tyr-Ile-(6) aminohexanoic amide, is an oligopeptide drug derived from angiotensin IV that binds with high affinity to hepatocyte growth factor (HGF) and potentiates its activity at its receptor, c-Met. Dihexa has been found to potently improve cognitive function in animal models of Alzheimer's disease-like mental impairment. In an assay of neurotrophic activity, Dihexa was found to be seven orders of magnitude more potent than brain-derived neurotrophic factor.an orally active, blood–brain barrier permeable compound was subsequently developed with the potential to treat Alzheimer's disease and other disorders that would benefit from augmented synaptic connectivity.

COMMON FORMULAS & PROTOCOLS

Dihexa (1mg) Capsule - One capsule daily for 30 days
Dihexa (2mg) Capsule - One capsule daily for 30 days

CLINICAL REFERENCES

1. Joseph W. Harding; John W. Wright; Caroline C. Benoist; Leen H. Kawas; Gary A. Wayman (3 December 2013). "Patent US 8598118 - Hepatocyte growth factor mimics as therapeutic agents". Retrieved 11 October 2015.
2. Alene T. McCoy; Caroline C. Benoist; John W. Wright; Leen H. Kawas; Jyote Bule-Ghogare; Mingyan Zhu; Suzanne M. Appleyard; Gary A. Wayman; Joseph W. Harding (January 2013). "Evaluation of metabolically stabilized angiotensin IV analogs as pro-cognitive/anti-dementia agents". The Journal of Pharmacology and Experimental Therapeutics. 344 (1): 141–154. doi: 10.1124/jpet.112.199497. PMC 3533412. PMID 23055539.

Additional references available. Contact us for more info.

CRE8 PHARMACY

CRE8 PHARMACY 3700 NW 126th Avenue, Coral Springs, FL 33065 888-224-5181 Toll Free 754-529-8294 Fax

GHK-Cu

PEPTIDE THERAPY

BENEFITS MAY INCLUDE

- Repairs skin barrier proteins
- Improved skin elasticity and firmness
- Reduces hyper-pigmentation and skin spots
- Stimulates skin collagen
- Improves overall skin appearance
- Reduces inflammation
- Improves wound healing and reduce infections
- Increases hair growth and follicle size

BRIEF OVERVIEW

GHK-Cu is a tripeptide with the amino acid sequence glycyl-histidyl-lysine. It naturally occurs in human plasma. It has also been found in saliva, and urine. In plasma the level of GHK declines as you age. This decline in the GHK-level coincides with the noticeable decrease in regenerative capacity of an organism. GHK-Cu functions as a complex with copper stimulates collagen production, accelerates wound healing and contraction, improves the take of transplanted skin, and also possesses anti-inflammatory properties.

COMMON FORMULAS & PROTOCOLS

GHK-Cu (5mg/ml) Organic Bio-Cream (facial) - Apply 1-2 pumps daily for 30 days
GHK-Cu (5mg/ml) Foam (scalp) - Apply 1ml to scalp nightly for 30 days
GHK-Cu / BPC-157 (2mg/2mg/ml) Organic Bio-Cream (facial) - Apply 1-2 pumps daily for 30 days

CLINICAL REFERENCES

1. L. Pickart, J. H. Freedman, W. J. Loker et al., "Growth-modulating plasma tripeptide may function by facilitating copper uptake into cells," Nature, vol. 288, no. 5792, pp. 715–717, 1980.
2. D. Downey, W. F. Larrabee Jr., V. Voci, and L. Pickart, "Acceleration of wound healing using glycyl-histidyl-lysine copper (II)," Surgical Forum, vol. 25, pp. 573–575, 1985.
3. H. Ehrlich, "Stimulation of skin healing in immunosuppressed rats," in Proceedings of the Symposium on Collagen and Skin Repair, Reims, France, September 1991.

Additional references available. Contact us for more info.

CRE8 PHARMACY

CRE8 PHARMACY 3700 NW 126th Avenue, Coral Springs, FL 33065 888-224-5181 Toll Free 754-529-8294 Fax

IBUTAMOREN (MK-677)

PEPTIDE THERAPY

BENEFITS MAY INCLUDE

- Promotes lipolysis
- Increased bone density
- Increase in lean body mass
- Increase muscle mass
- Improves sleep quality
- Increased energy
- Increased endurance
- Improved cellular repair
- Increased IGF-1
- Supports cognitive performance
- Supports joint health



BRIEF OVERVIEW

Ibutamoren (MK-677) is a potent, long-acting, orally-active, selective, and non-peptide agonist of the ghrelin receptor and a growth hormone secretagogue, mimicking the growth hormone (GH)-stimulating action of the endogenous hormone ghrelin. It has been shown to increase the secretion of several hormones including GH and insulin-like growth factor 1 (IGF-1) and produces sustained increases in the plasma levels of these hormones without affecting cortisol levels.

COMMON FORMULAS & PROTOCOLS

Ibutamoren (MK-677) 12.5mg Capsule - One capsule daily on an empty stomach for 30 days
Ibutamoren (MK-677) 25mg Capsule - One capsule daily on an empty stomach for 30 days
Ibutamoren (MK-677) 25mg Troche - One troche daily on an empty stomach for 30 days

CLINICAL REFERENCES

1. Patchett AA, Nargund RP, Tata JR, Chen MH, Barakat KJ, Johnston DB, Cheng K, Chan WW, Butler B, Hickey G (July 1995). "Design and biological activities of L-163,191 (MK-0677): a potent, orally active growth hormone secretagogue". Proceedings of the National Academy of Sciences of the United States of America. 92 (15): 7001–5. doi:10.1073/pnas.92.15.7001. PMC 41459.
2. Chapman IM, Pescovitz OH, Murphy G, Treep T, Cerchio KA, Krupa D, Gertz B, Polvino WJ, Skiles EH, Pezzoli SS, Thorner MO (October 1997). "Oral administration of growth hormone (GH) releasing peptide-mimetic MK-677 stimulates the GH/insulin-like growth factor-I axis in selected GH-deficient adults". The Journal of Clinical Endocrinology and Metabolism. 82 (10): 3455–63. doi:10.1210/jc.82.10.3455. PMID 9329386.

Additional references available. Contact us for more info.

CRE8 PHARMACY

CRE8 PHARMACY 3700 NW 126th Avenue, Coral Springs, FL 33065 888-224-5181 Toll Free 754-529-8294 Fax

IPAMORELIN

PEPTIDE THERAPY

BENEFITS MAY INCLUDE

- Promotes lipolysis
- Increased collagen production
- Increase in lean body mass
- Improves sleep quality
- Increased energy
- Increased endurance
- Improved cellular repair
- Increased IGF-1
- Counteracts glucocorticoid catabolic effects
- Less appetite stimulation
- Less release of cortisol, prolactin and aldosterone



BRIEF OVERVIEW

Ipamorelin is a pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) and a ghrelin mimetic with growth hormone (GH) releasing activity. Ipamorelin mimics ghrelin and binds to the ghrelin receptor (or GH secretagogue receptor, GHSR) in the brain, thereby selectively stimulating the release of GH from the pituitary gland. This results in increased plasma GH levels, which would affect many biological processes. Besides its presence in the brain, GHSR can also be found in the gastrointestinal tract, heart, lung, liver, kidney, pancreas, adipose tissue and immune cells. Unlike other GH releasing peptides, Ipamorelin only stimulates GH release in a manner very similar to that of growth hormone releasing hormone.

COMMON FORMULAS & PROTOCOLS

Ipamorelin (9mg) Lyophilized Vial - 300mcg SQ injection daily for 30 days
Ipamorelin (300mcg) Sublingual Troche - One troche daily for 30 days
CJC-1295 / Ipamorelin (4/4mg) Lyophilized Vial - 200/200mcg daily SQ injection 5 days on, 2 days off
CJC-1295 / Ipamorelin (5/9mg) Lyophilized Vial - 250/450mcg daily SQ 5 injection days on, 2 days off

CLINICAL REFERENCES

1. Gobburu, Jogarao V. S.; Agersø, Henrik; Jusko, William J.; Ynddal, Lars (1999).Pharmacokinetic Modeling of Ipamorelin, a Growth Hormone Releasing Peptide, in Human Volunteers". Pharmaceutical Research. 16 (9): 1412–1416. doi:10.1023/A:1018955126402. ISSN 0724-8741.
2. Raun, K; Hansen, B.; Johansen, N.; Thogersen, H; Madsen, K; Ankersen, M; Andersen, P. (1998). "Ipamorelin, the first selective growth hormone secretagogue". European Journal of Endocrinology. 139 (5): 552–561. doi:10.1530/eje.0.1390552. ISSN 0804-4643.

Additional references available. Contact us for more info.

CRE8 PHARMACY

CRE8 PHARMACY 3700 NW 126th Avenue, Coral Springs, FL 33065 888-224-5181 Toll Free 754-529-8294 Fax

SERMORELIN ACETATE

PEPTIDE THERAPY

BENEFITS MAY INCLUDE

- Increase in lean body mass
- Promotes lipolysis
- Increased energy
- Increased strength
- Accelerated wound healing
- Improved cardiovascular and immune function
- Improves sleep quality
- Improved bone density
- Improved skin quality and higher collagen density
- Increased IGF-1



BRIEF OVERVIEW

Sermorelin (brand names Geref), is a peptide analogue of growth hormone-releasing hormone (GHRH) which is used as a diagnostic agent to assess growth hormone (GH) secretion for the purpose of diagnosing growth hormone deficiency. It is a 29-amino acid polypeptide representing the 1–29 fragment from endogenous human GHRH, thought to be the shortest fully functional fragment of GHRH.

COMMON FORMULAS & PROTOCOLS

Sermorelin (9mg) Freeze Dried Vial - 300mcg SQ injection nightly for 30 days
Sermorelin (15mg) Freeze Dried Vial - 500mcg SQ injection nightly for 30 days
Sermorelin (300mcg) Sublingual Troche - One troche daily for 30 days
Sermorelin (500mcg) Sublingual Troche - One troche daily for 30 days

CLINICAL REFERENCES

1. Prakash A, Goa KL (August 1999). "Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency". BioDrugs. 12 (2): 139–57. doi:10.2165/00063030-199912020-00007. PMID 18031173.
2. Pharmacology (Rang, Dale, Ritter & Moore, ISBN 0-443-07145-4, 5th ed., Churchill Livingstone 2003).

Additional references available. Contact us for more info.

CRE8 PHARMACY

CRE8 PHARMACY 3700 NW 126th Avenue, Coral Springs, FL 33065 888-224-5181 Toll Free 754-529-8294 Fax

TESOFENSINE

PEPTIDE THERAPY

BENEFITS MAY INCLUDE

- Promotes lipolysis
- Increased energy
- Increase in lean body mass
- Stimulates metabolism
- Appetite suppression
- Improves sleep quality
- Decrease hemoglobin A1C and insulin levels
- Decrease triglycerides and cholesterol

BRIEF OVERVIEW

Tesofensine is a serotonin–noradrenaline–dopamine reuptake inhibitor from the phenyltropane family of drugs. Originally, Tesofensine was developed by a biotechnology company for the treatment of Alzheimer's and Parkinson's disease but was subsequently dropped from development for these applications after early trial results showed limited efficacy for treatment of these diseases. However, weight loss was consistently reported as an adverse event in the original studies, especially in overweight or obese patients thus changing the course of clinical trials towards the treatment of obesity. Tesofensine primarily acts as an appetite suppressant, but additionally can act by increasing resting energy expenditure.

COMMON FORMULAS & PROTOCOLS

Tesofensine (500mcg) Capsule - One capsule daily for 30 days

CLINICAL REFERENCES

1. Jo–Anne Gilbert , Christoph Gasteyger , Anne Raben, Dieter H. Meier, Arne Astrup, Anders Sjödin. “The Effect of Tesofensine on Appetite Sensations”. https://doi.org/10.1038/oby.2011.197
2. Astrup A, Madsbad S, Breum L, Jensen TJ, Kroustrup JP, Larsen TM (2008). "Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomized, double-blind, placebo-controlled trial". Lancet. 372 (9653): 1906–13. doi:10.1016/S0140-6736(08)61525-1. PMID 18950853.

Additional references available. Contact us for more info.

CRE8 PHARMACY

CRE8 PHARMACY 3700 NW 126th Avenue, Coral Springs, FL 33065 888-224-5181 Toll Free 754-529-8294 Fax

THYMOSIN ALPHA-1

PEPTIDE THERAPY

BENEFITS MAY INCLUDE

- Modulates immune function and inflammation
- Improved chronic fatigue
- Suppresses tumor growth
- Improved autoimmune function
- Anti-fungal and anti-bacterial properties
- Protects against oxidative damage
- Lyme Disease treatment
- Increases vaccine effectiveness
- Helps eliminate unhealthy cells and stop infection or cancer growth

BRIEF OVERVIEW

Thymosin Alpha-1 has been known as an excellent immune modulator. Thymosin is a small protein produced naturally by the thymus gland which stimulates the development of disease-fighting T cells. The thymus is an integral part of your immune system, where individual T-cells are made to respond to the millions of bacteria, fungi, or viruses that could invade your body. Commonly prescribed for the treatment for chronic viral diseases, Thymosin Alpha-1 has also been shown to increase innate immunity factors and help fight against harmful autoimmune processes. It is given to help control inflammation associated with chronic diseases, which can cause excess fatigue.

COMMON FORMULAS & PROTOCOLS

Thymosin Alpha-1 (15mg) Vial - 450mcg SQ injection daily for 30 days
Thymosin Alpha-1 (2000mcg/ml) Nasal Spray 15ml Bottle - 200mcg (1-2 sprays) each nostril daily

CLINICAL REFERENCES

1. You J, Zhuang L, Cheng HY, Yan SM, Yu L, Huang JH, Tang BZ, Huang ML, Ma YL, Chongsuvivatwong V, et al. World J Gastroenterol. Efficacy of thymosin alpha-1 and interferon alpha in treatment of chronic viral hepatitis B: 2006 Nov 7; 12(41): 6715-21.
2. Sherman KE, Sjogren M, Creager RL, Damiano MA, Freeman S, Lewey S, Davis D, Root S, Weber FL, Ishak KG, et al. Hepatology. Combination therapy with thymosin alpha1 and interferon for the treatment of chronic hepatitis C infection: a randomized, placebo-controlled double-blind trial. 1998 Apr; 27(4):1128-35.

Additional references available. Contact us for more info.

CRE8 PHARMACY

CRE8 PHARMACY 3700 NW 126th Avenue, Coral Springs, FL 33065 888-224-5181 Toll Free 754-529-8294 Fax

ZINC THYMULIN

PEPTIDE THERAPY

BENEFITS MAY INCLUDE

- Improves hair growth
- Prevent hair loss
- Improves endogenous hair pigmentation
- Treatment for androgenic alopecia
- Useful for both male and female
- Can be combined with alternate hair growth protocols

BRIEF OVERVIEW

Zinc Thymulin (also known as thymic factor) is a nonapeptide produced by two distinct epithelial populations in the thymus first described by Bach in 1977. Its biological activity and antigenicity depend upon the presence of the metal zinc in the molecule. This pharmacologically active metallopeptide induces the differentiation of T-cells and enhances several functions of the various T-cell subsets in normal or partially thymus-deficient recipients. Zinc Thymulin has been used for the treatment of hair loss. A recent study indicated that topical treatment with zinc thymulin increased hair growth over 6 months; furthermore, there were no systemic or local side effects from the treatment. The zinc thymulin metallo-peptide optionally also improves endogenous hair pigmentation by stimulating melanogenesis in grey hair.

COMMON FORMULAS & PROTOCOLS

Zinc Thymulin Topical 50mcg/ml Foam (scalp) 30ml Bottle - Apply 1ml to scalp nightly before bed

CLINICAL REFERENCES

1. Meier N, Langan D, Hilbig H, Bodo E, Farjo NP, et al. (2012) Thymic peptides differentially modulate human hair follicle growth. J Invest Dermatol 132: 1516-1519.
2. Renner D, Schuster D, Heim ME (1986) Experiences using the "thymu-skin" hair cure for the prevention of alopecia in cytostatic treatment. Onkologie 5: 285-286

Additional references available. Contact us for more info.

CRE8 PHARMACY

PEPTIDE THERAPY

FORMULAS & DOSING

PEPTIDE LYOPHILIZED INJECTABLE FORMULAS

DESCRIPTION	SIZE/STRENGTH	30 DAY DOSE
BPC-157	10 mg vial	300 mcg
Bremelanotide (PT-141) w/B6	10mg/ml (2ml vial)	0.1 - 0.2ml before sexual activity
CJC-1295	10 mg vial	300 mcg
CJC-1295 / Ipamorelin	4/4 mg vial	200/200 mcg
CJC-1295 / Ipamorelin	5/9 mg vial	250/450 mcg
Ipamorelin	9 mg vial	300 mcg
Sermorelin	9 mg vial	300 mcg
	15 mg vial	500 mcg
Thymosin Alpha-1	3mg/ml (5ml vial)	450 mcg

PEPTIDE ORAL TROCHE FORMULAS *(other strengths available)*

DESCRIPTION	SIZE/STRENGTH
BPC-157	500 mcg, 1000mcg
CJC-1295 / Ipamorelin	300/300 mcg
Ipamorelin	300 mcg, 500 mcg
Sermorelin Acetate	300 mcg, 500 mcg
Sermorelin / Ipamorelin	300/300mcg

OTHER PEPTIDE FORMULAS

DESCRIPTION	SIZE/STRENGTH
BPC-157 Capsule	500 mcg, 1000mcg
BPC-157 Anti-Inflammatory Cream	1mg/ml (30g)
BPC-157 Organic Bio-Cream (facial)	1mg/ml (30g)
BPC-157 Suppository	500 mcg, 1000mcg
Bremelanotide (PT-141) w/B6 Nasal Spray	5mg/25mg/ml (10ml bottle)
Dihexa Capsule	1mg, 2mg, 10mg
GHK-Cu Organic Bio-Cream	5mg/ml (15ml bottle)
GHK-Cu Topical Foam	5mg/ml (30ml bottle)
GHK-Cu w/ BPC-157 Organic Bio-Cream	2mg/2mg/ml (15ml bottle)
Ibutamoren (MK-677) Capsules	12.5 mg, 25 mg
Tesofensine Capsule	500mcg
Thymosin Alpha-1 Nasal Spray	2000mcg/ml (15ml bottle)
Zinc Thymulin Topical Foam	50mcg/ml (30ml bottle)

Multiple strength/blends for any non sterile formulas can be compounded as prescribed

CRE8 PHARMACY

CRE8 PHARMACY 3700 NW 126th Avenue, Coral Springs, FL 33065 888-224-5181 Toll Free 754-529-8294 Fax

ADDITIONAL REFERENCES

BPC-157

1. Sikiric P, et al. Brain-gut Axis and Pentadecapeptide BPC 157: Theoretical and Practical Implications. Curr Neuropharmacol. (2016)
2. Klicek R, et al. Stable gastric pentadecapeptide BPC 157 heals cysteamine-colitis and colon-colon-anastomosis and counteracts cuprizone brain injuries and motor disability. J Physiol Pharmacol. (2013)
3. Chang CH, et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol (1985). (2011)
4. Staresinic M, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. J Orthop Res. (2003)
5. Jenkins TA, et al. Influence of Tryptophan and Serotonin on Mood and Cognition with a Possible Role of the Gut-Brain Axis. Nutrients. (2016)

BREMELANOTIDE (PT-141)

1. Anita H Clayton*, Stanley E Althof, Sheryl Kingsberg, Leonard R DeRogatis, Robin Kroll, Irwin Goldstein, Jed Kaminetsky, Carl Spana, Johna Lucas, Robert Jordan, David J Portman 2016 - Bremelanotide for Female Sexual Dysfunctions in Premenopausal Women: A Randomized, Placebo-Controlled Dose-Finding Trial
2. D.C. Earlea, W.D. Garciab, C. SpanaaCo-administration of low doses of intranasal PT-141, a melanocortin receptor agonist, and sildenafil to men with erectile dysfunction results in an enhanced erectile response https://doi.org/10.1016/j.urology.2004.10.060

CJC-1295

1. Jetté, Lucie; Léger, Roger; Thibaudeau, Karen; Benquet, Corinne; Robitaille, Martin; Pellerin, Isabelle; Paradis, Véronique; van Wyk, Pieter; Pham, Khan; Bridon, Dominique P. (2005). "Human Growth Hormone-Releasing Factor (hGRF)1–29-Albumin Bioconjugates Activate the GRF Receptor on the Anterior Pituitary in Rats: Identification of CJC-1295 as a Long-Lasting GRF Analog" (PDF). Endocrinology. 146 (7): 3052–3058. doi:10.1210/en.2004-1286. ISSN 0013-7227. PMID 15817669.
2. Teichman, Sam L.; Neale, Ann; Lawrence, Betty; Gagnon, Catherine; Castaigne, Jean-Paul; Frohman, Lawrence A. (2006). "Prolonged Stimulation of Growth Hormone (GH) and Insulin-Like Growth Factor I Secretion by CJC-1295, a Long-Acting Analog of GH-Releasing Hormone, in Healthy Adults". The Journal of Clinical Endocrinology & Metabolism. 91 (3): 799–805. doi:10.1210/jc.2005-1536. ISSN 0021-972X. PMID 16352683.
3. Ionescu, Madalina; Frohman, Lawrence A. (2006). "Pulsatile Secretion of Growth Hormone (GH) Persists during Continuous Stimulation by CJC-1295, a Long-Acting GH-Releasing Hormone Analog". The Journal of Clinical Endocrinology & Metabolism. 91 (12): 4792–4797. doi:10.1210/jc.2006-1702. ISSN 0021-972X.
4. Henninge, John; Pepaj, Milaim; Hullstein, Ingunn; Hemmersbach, Peter (2010). "Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation". Drug Testing and Analysis. 2 (11–12): 647–650. doi:10.1002/dta.233. ISSN 1942-7603.
5. Thorner, Michael O. (2008). "The Discovery of Growth Hormone-Releasing Hormone1: An Update". Journal of Neuroendocrinology. 20 (6): 653–654. doi:10.1111/j.1365-2826.2008.01740.x. ISSN 0953-8194.

CRE8 PHARMACY

ADDITIONAL REFERENCES

DIHEXA

1. Benoist CC, Kawas LH, Zhu M, Tyson KA, Stillmaker L, Appleyard SM, Wright JW, Wayman GA, Harding JW (November 2014). "The Procognitive and Synaptogenic Effects of Angiotensin IV-Derived Peptides Are Dependent on Activation of the Hepatocyte Growth Factor/c-Met System". The Journal of Pharmacology and Experimental Therapeutics. 351 (2): 390–402. doi: 10.1124/jpet.114.218735. PMC 4201273. PMID 25187433.
2. Caroline C. Benoist; John W. Wright; Mingyan Zhu; Suzanne M. Appleyard; Gary A. Wayman; Joseph W. Harding (October 2011). "Facilitation of Hippocampal Synaptogenesis and Spatial Memory by C-Terminal Truncated Nle1-Angiotensin IV Analogs". The Journal of Pharmacology and Experimental Therapeutics. 339 (1): 35–44. doi:10.1124/jpet.111.182220. PMC 3186286. PMID 21719467.
3. Phillip M. Uribe; Leen H. Kawas; Joseph W. Harding; Allison B. Coffin (January 2015). "Hepatocyte growth factor mimetic protects lateral line hair cells from aminoglycoside exposure". Frontiers in Cellular Neuroscience. 9 (3). doi:10.3389/fncel. 2015.00003. PMC 4309183. PMID 25674052.
4. John W. Wright; Joseph W. Harding (January 2015). "The Brain Hepatocyte Growth Factor/c-Met Receptor System: A New Target for the Treatment of Alzheimer's Disease". Journal of Alzheimer's Disease. 45 (4): 985–1000. doi:10.3233/JAD-142814. PMID 25649658.

GHK-Cu

1. L. Pickart, A Tripeptide from Human Serum Which Enhances the Growth of Neoplastic Hepatocytes and the Survival of Normal Hepatocytes, University of California, San Francisco, Calif, USA, 1973.
2. L. Pickart, "Iamin: a human growth factor with multiple wound-healing properties," in Biology of Copper Complexes, J. Sorenson, Ed., pp. 273–285, Humana Press, Clifton, NJ, USA, 1987.
3. F. Buffoni, R. Pino, and A. Dal Pozzo, "Effect of tripeptide-copper complexes on the process of skin wound healing and on cultured fibroblasts," Archives Internationales de Pharmacodynamie et de Therapie, vol. 330, no. 3, pp. 345–360, 1995.

IBUTAMOREN (MK-677)

1. Copinschi G, Van Onderbergen A, L'Hermite-Balériaux M, Mendel CM, Caufriez A, Leproult R, Bolognese JA, De Smet M, Thorner MO, Van Cauter E (August 1996). "Effects of a 7-day treatment with a novel, orally active, growth hormone (GH) secretagogue, MK-677, on 24-hour GH profiles, insulin-like growth factor I, and adrenocortical function in normal young men". The Journal of Clinical Endocrinology and Metabolism. 81 (8): 2776–82. doi:10.1210/jcem.81.8.8768828. PMID 8768828.
2. Thorner MO, Chapman IM, Gaylinn BD, Pezzoli SS, Hartman ML (1997). "Growth hormone-releasing hormone and growth hormone-releasing peptide as therapeutic agents to enhance growth hormone secretion in disease and aging". Recent Progress in Hormone Research. 52: 215–44, discussion 244-6. PMID 9238854.
3. Murphy MG, Bach MA, Plotkin D, Bolognese J, Ng J, Krupa D, Cerchio K, Gertz BJ (July 1999). "Oral administration of the growth hormone secretagogue MK-677 increases markers of bone turnover in healthy and functionally impaired elderly adults. The MK-677 Study Group". Journal of Bone and Mineral Research. 14 (7): 1182–8. doi:10.1359/jbmr.1999.14.7.1182. PMID 10404019.
4. Patchett AA, Nargund RP, Tata JR, Chen MH, Barakat KJ, Johnston DB, Cheng K, Chan WW, Butler B, Hickey G (July 1995). "Design and biological activities of L-163,191 (MK-0677): a potent, orally active growth hormone secretagogue". Proceedings of the National Academy of Sciences of the United States of America. 92 (15): 7001–5. doi:10.1073/pnas.92.15.7001. PMC 41459. PMID 7624358.

IPAMORELIN

1 Gobburu, Jogarao V. S.; Agersø, Henrik; Jusko, William J.; Ynddal, Lars (1999). "Pharmacokinetic-Pharmacodynamic Modeling of Ipamorelin, a Growth Hormone Releasing Peptide, in Human Volunteers". Pharmaceutical Research. 16 (9): 1412–1416. doi:10.1023/A: 1018955126402. ISSN 0724-8741.

2 Moulin, Aline; Ryan, Joanne; Martinez, Jean; Fehrentz, Jean-Alain (2007). "Recent Developments in Ghrelin Receptor Ligands". ChemMedChem. 2 (9): 1242–1259. doi:10.1002/cmdc.200700015. ISSN 1860-7179. PMID 17520591.

3 Raun, K; Hansen, B.; Johansen, N.; Thogersen, H; Madsen, K; Ankersen, M; Andersen, P. (1998). "Ipamorelin, the first selective growth hormone secretagogue". European Journal of Endocrinology. 139 (5): 552–561. doi:10.1530/eje.0.1390552. ISSN 0804-4643.

4 Estrada, R. Cañete; Jiménez-Reina, L.; de la Torre, M.J.; Bernal, J. (2002). "Chronic In Vivo Ipamorelin Treatment Stimulates Body Weight Gain and Growth Hormone (GH) Release In Vitro in Young Female Rats". 6 (1): 37–46. ISSN 1136-4890.

CRE8 PHARMACY

ADDITIONAL REFERENCES

SERMORELIN

1. Vitiello MV, Schwartz RS, Moe KE, Mazzoni G, Merriam GR. 2001 Treating age-related changes in somatotrophic hormones, sleep, and cognition. In Health, age, hormones, sleep, and cognition Dialogues in Clinical Neuroscience – Vol 3. No. 3.
2. Esposito P, Barbero L, Caccia P, Caliceti P, D'Antonio M, Piquet G, Veronese FM: PEGylation of growth hormone-releasing hormone (GRF) analogues. Adv Drug Deliv Rev. 2003 Sep 26;55(10):1279-91. [PubMed:14499707]
3. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
4. Toogood AA, Beardwell CG, Shalet SM. 1994 The severity of growth hormone deficiency in adults with pituitary disease is related to the degree of hypopituitarism. Clin Endocrinol (Oxf). 41:511–516.
5. Merriam GR, Schwartz RS, Vitiello MV. Growth hormone-releasing hormone and growth hormone secretagogues in normal aging. Endocrine. 2003 Oct; 22(1):41-8.
6. Walker, R.F., 2006. Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? Clin Interv Aging, 1(4): p. 307-8.
7. Khorram O, Laughlin GA, Yen SS. Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advancing men and women. J Clin Endocrinol Metab. 1997 May; 82(5):1472-9.

TESOFENSINE

1. Astrup A, Breum L, Jensen TJ, Kroustrup JP, Larsen TM. Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial. Lancet 2008;372:1906-13" (PDF). 18 (7): 1043–6. doi:10.1517/13543780902967632.
2. Marks, D.; Pae, C.; Patkar, A. (2008). "Triple reuptake inhibitors: the next generation of antidepressants". Current Neuropharmacology. 6 (4): 338–343. doi:10.2174/157015908787386078.

THYMOSIN ALPHA-1

1. Low TL, Goldstein AL. Thymus. 1984; 6(1-2):27-42. Thymosins: structure, function and therapeutic applications.
2. King R, Tuthill C. Vitam Horm. 2016; 102:151-78. Epub 2016 May 24. Immune Modulation with Thymosin Alpha 1 Treatment.
3. Sherman KE. Ann N Y Acad Sci. 2010 Apr; 1194:136-40. Thymosin alpha 1 for treatment of hepatitis C virus: promise and proof.
4. Fanwen Wang, Tingting Yu, Heng Zheng & Xingzhen Lao. Thymosin Alpha1-Fc Modulates the Immune System and Down-regulates the Progression of Melanoma and Breast Cancer with a Prolonged Half-life Article number: 12351 (2018)

ZINC THYMULIN

1. Meier N, Langan D, Hilbig H, Bodo E, Farjo NP, et al. (2012) Thymic peptides differentially modulate human hair follicle growth. J Invest Dermatol 132: 1516-1519.
2. Dardenne M, Pleau JM (1994) Interactions between zinc and thymulin. Met Based Drugs 1: 233-239
3. Famenini S, Goh C (2014) Evidence for supplemental treatments in androgenetic alopecia. J Drugs Dermatol 13: 809-812

CRE8 PHARMACY